Michael Richardson

Dr. Michael Richardson

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Cancer Control
Verified
Journal Article
Open access
MRMichael Richardson
Michael Richardson
KAKristopher Attwood
Kristopher Attwood
GSGabriella Smith
Gabriella Smith
SLSu-Ying Liang
Su-Ying Liang
KMKatherine LaVigne Mager
Katherine LaVigne Mager
BMBradley J. Monk
Bradley J. Monk
Objectives: To evaluate outcomes and cost-effectiveness of targeted therapy sequencing for metastatic and recurrent cervical cancer. Method: Models were simulated based on phase II and III trials on bevacizumab (bev) from GOG-240, cemiplimab (cemi) from GOG 3016, pembrolizumab (pembro) from KEYNOTE-826, and tisotumab vedotin (tiso) from GOG 3023. Costs were based on IBM Micromedex RED BOOK™ and company listed costs. Results: For [chemo + bev → chemo], total cost was $125,918.04, with median overall survival (mOS) of 21.8 months, and cost-effectiveness ratio (CER) of $119,835.79. For [chemo + bev → cemi], total cost was $187,562.99 with mOS of 28.5 months and CER of $162,039.16. For [chemo + bev + pembro → chemo], total cost was $319,963.78 with mOS 32.9 months and CER of $249,930.10. For [chemo + bev + pembro → tiso], total cost was $455,204.45, with mOS 36.5 months and CER of $320,072.99. Conclusion: The combination of immunotherapies and biologics have significantly increased overall survival, but with associated higher costs, primarily related to drug costs.

11 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
MRMichael Richardson
Michael Richardson
MRMaria Sol Recouvreux
Maria Sol Recouvreux
BKBeth Y. Karlan
Beth Y. Karlan
AWAnn E. Walts
Ann E. Walts
SOSandra Orsulic
Sandra Orsulic
Ciliated cell markers expressed in epithelial ovarian cancers (EOC) are associated with improved survival. We examined the distribution of cells expressing ciliated cell markers in various EOC histologies and stages. Immunohistochemistry and/or multiplex immunofluorescence were used to determine the expression of FOXJ1 and/or CAPS (ciliated cell markers) in tissue microarrays including 4 normal fallopian tubes, 6 normal endometria, 16 cystadenomas, 25 borderline tumors, 21 low-grade carcinomas, and 118 high-grade carcinomas (HGSOC) (46 serous, 29 endometrioid, 30 clear cell, 13 mucinous). CAPS+ cells were observed in normal fallopian tubes and endometria and in ~85% of serous benign and borderline tumors and low-grade carcinomas but only in <40% of HGSOC. mRNA data from an independent cohort showed higher FOXJ1 and CAPS expression in serous borderline tumors and low-grade carcinomas compared to HGSOC. In HGSOC, ciliated cell-positive markers were observed in 52% primary tumors compared to 26% of patient-matched synchronous metastases, and 24% metachronous metastases (p = 0.009). mRNA data from an independent HGSOC cohort showed lower levels of CAPS in metastases than in primary tumors (p = 0.03). Overall, the study revealed that ciliated cells were less common in mucinous EOC, the percentage of ciliated cell marker-positive cases decreased with increasing grade, and the percentage of ciliated cells decreased in HGSOC metastases compared to patient-matched primary tumors.

1 February 2021 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
EDElisabeth Diver
Elisabeth Diver
MRMichael Richardson
Michael Richardson
CLCheng-I Liao
Cheng-I Liao
AMAmandeep K Mann
Amandeep K Mann
KDKathleen M Darcy
Kathleen M Darcy
JCJohn K Chan
John K Chan
Objective Gestational trophoblastic neoplasia are a group of diseases with few data given their rarity. The aim of this study was to determine the age and racial differences in the presentation and survival of patients with gestational trophoblastic neoplasia in the United States. Methods Data were collected from the National Cancer Database from January 2004 to December 2014. Chi-square tests, Cox regression, and Kaplan–Meier models were performed. Demographic characteristics included age at diagnosis, race, insurance status, facility location and type, community median income, high school dropout rate, education, income, and population density data. Results There were 1004 eligible patients including 64% white (n=645), 23% black (n=233), and 8.3% Asian patients (n=83). Median age was 30.8 (range 14–59) years. Stage I, II, III, IV, and unknown were diagnosed in 32%, 5.4%, 30%, 18%, and 15% of patients, respectively, with 5-year survival of 99%, 93%, 94%, 72%, and 95%, respectively (p<0.001). Compared with national birth rates, those with gestational trophoblastic neoplasia were overrepresented at younger (age 10–19 years: 8.2% vs 4.8%) and older ages (age 40–54 years: 17% vs 3.3%). The extremes of age at presentation were more pronounced in black patients with gestational trophoblastic neoplasia (age 10–19 years: 11% vs 6.9%, 40–54 years: 18% vs 3.2%), and black patients constituted 23% of patients compared with 15% of births nationwide. Some 59% of patients were treated at Academic/Research Programs. Only 6/448 (1.3%) facilities treated more than one patient per year, and only 9% (n=92) of patients were treated at one of these high-volume facilities. On multivariable analysis, older age, higher Charlson/Deyo co-morbidity score, and higher stage disease were independently associated with worse survival (all p<0.001). Conclusions Gestational trophoblastic neoplasia was disproportionately higher in those at extremes of age and in black women as compared with United States national data. The lack of centralization of care justifies the need to develop regional centers of excellence for this rare malignancy.

21 December 2023 in Gynecologic Oncology
Verified
Journal Article
Closed access
JCJohn K. Chan
John K. Chan
CTChunqiao Tian
Chunqiao Tian
JKJoshua P. Kesterson
Joshua P. Kesterson
KLKen Y. Lin
Ken Y. Lin
KDKathleen M Darcy
Kathleen M Darcy
JBJeffery G. Bell
Jeffery G. Bell

1 December 2018 in Journal of Palliative Medicine
Verified
Journal Article
Open access
MAMuthuraman Alagappan
Muthuraman Alagappan
MRMichael Richardson
Michael Richardson
MSMatthew K. Schoen
Matthew K. Schoen
LMLori Muffly
Lori Muffly
KTKathryn Tierney
Kathryn Tierney
VPVyjeyanthi S. Periyakoil
Vyjeyanthi S. Periyakoil
Background: Little is known about the extent of alignment between hematopoietic stem cell transplant (HSCT) patients and their healthcare proxies with respect to advance care planning (ACP). Aim: To determine if a structured three-step process using the letter advance directive (LAD) could (1) allow for the differences in opinion between patient–proxy dyads to surface and (2) help bridge preexisting discordance about specific treatment choices. Design: Blinded to each other, the HSCT patient (LAD-1) and proxy (LAD-2) each completed the LAD (step 1). They unmasked, compared LAD-1 and LAD-2, and discussed their choices (step 2). They completed a final letter directive (LAD-3) by consensus (step 3). Settings/Participants: Convenience sample of eighty dyads (patient and proxy) at a regional HSCT referral center. Results: The mean patient–proxy concordance was 72.9% for the 12 questions in the LAD. Wanting to be pain free at the end of life was the statement with the most amount of agreement (88.75% in LAD-1, 91.25% in LAD-2, and 90% in LAD-3). Patient–proxy dyads had notable discordance related to specific treatments. The highest discordance was related to ventilator support (46.3% of patients refused it, while 58.8% of proxies refused on behalf of the patient). Overall, proxies were more likely than patients to opt in for dialyses and hospice care but more likely to opt out for cardiac resuscitation and sedation to palliate refractory symptoms. On open discussion, patient–proxy discordance mostly resolved in favor of the patient. Conclusions: The ACP process should allow for patient–proxy differences to surface, facilitate a discussion about the granular details with the goal of reaching consensus. Our three-step approach using the LAD is an effective way to identify areas of patient–proxy concordance and discordance about specific treatment preferences. A structured patient–proxy discussion using the LAD helped reconcile discordance and most often in favor of a patient's original wishes.

16 September 2022 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
SLSu‐Ying Liang
Su‐Ying Liang
MRMichael Richardson
Michael Richardson
DWDeanna Wong
Deanna Wong
TCTony Chen
Tony Chen
NCNatalia Colocci
Natalia Colocci
JCJohn K. Chan
John K. Chan